Drug delivery methods, structures, and compositions for nasolacrimal system
A drug insert is configured for use with an implant. The implant is configured for insertion into a lacrimal canaliculus. The drug insert includes a drug core comprising a therapeutic agent and a polymer; and a sheath body comprising material substantially impermeable to the therapeutic agent, wherein the drug core is positioned within the sheath body. The sheath body is configured to provide an exposed end of the drug core that releases therapeutic agent to an eye when the drug insert is disposed within the implant and the implant is positioned in the lacrimal canaliculus. A distal end of the drug core is sealed with a medical-grade adhesive.
1. A method for delivering a therapeutic agent to an eye comprising:
placing a punctal plug into a lacrimal canaliculus of a patient, wherein the punctal plug comprises:
a silicone plug body comprising a drug insert;
the drug insert comprising:
a drug core comprising a therapeutic agent contained in a matrix, and
an impermeable sheath body partially covering the drug core,
wherein when the punctal plug is inserted into the lacrimal canaliculus of the patient an exposed surface of the drug core is in direct contact with tear fluid to permit diffusion of the therapeutic agent into the tear fluid of the eye of the patient.
2. The method of claim 1 , wherein the sheath body is comprised of at least one of polyimide or polyethylene terephthalate.
3. The method of claim 1 , wherein the therapeutic agent comprises a prostaglandin analogue.
4. The method of claim 3 , wherein the prostaglandin analogue is selected from the group consisting of latanoprost, bimatoprost, and travoprost.
5. The method of claim 1 , wherein the therapeutic agent is a thrombin inhibitor, anti-glaucoma medication, a non-steroidal anti-inflammatory drug (NSAID), a fibrinolytic agent, a vasospasm inhibitor, a vasodilator, an antimicrobial agents, an antifungal, an antiviral, an anticancer chemotherapeutic agent, an anti-inflammatory agent, a hormonal agent, an immunosuppressive agent, a growth hormone antagonist, a growth factor, an angiogenesis inhibitor, a lubricant, a surfactant, a peptide, a protein, or an enzymes.
6. The method of claim 5 , wherein the therapeutic agent is dexamethasone, diclofenac, or a peptide.
7. The method of claim 1 , wherein the drug core comprises inclusions of the therapeutic agent contained in the matrix.
8. The method of claim 1 , wherein the matrix comprises a non-biodegradable polymer.
9. The method of claim 8 , wherein the non-biodegradable polymer is selected from the group consisting of silicone, an acrylate, a polyethylene, polyurethane, and polyester.
10. The method of claim 1 , wherein the drug core comprises a silicone matrix.
11. The method of claim 1 , wherein the drug core comprises a biodegradeable polymer matrix.
12. The method of claim 11 , wherein the biodegradable polymer is selected from protein, hydrogel, polyglycolic acid (PGA), polylactic acid (PLA), poly(L-lactic acid) (PLLA), poly(L-glycolic acid) (PLGA), polyglycolide, poly-L-lactide, poly-D-lactide, poly(amino acids), polydioxanone, polycaprolactone, polygluconate, polylactic acid-polyethylene oxide copolymers, modified cellulose, collagen, polyorthoesters, polyhydroxybutyrate, polyanhydride, polyphosphoester, poly(alpha-hydroxy acid) and combinations thereof.
13. The method of claim 1 , wherein the drug insert is further configured to release the therapeutic agent for at least 21 days.
14. The method of claim 11 , wherein the therapeutic agent treats glaucoma, post-surgical inflammation, dry eye, post-surgical pain, infection, or allergies.
15. A method for delivering a therapeutic agent to an eye comprising:
placing a punctal plug into a lacrimal canaliculus of a patient, wherein the punctal plug comprises:
a silicone plug body comprising a drug insert;
the drug insert comprising:
a drug core comprising a therapeutic agent contained in a matrix, wherein the therapeutic agent is selected from a prostaglandin analogue, a non-steroidal anti-inflammatory drug (NSAID), an anti-inflammatory agent or a an immunosuppressive agent, and
an impermeable sheath body partially covering the drug core,
wherein when the punctal plug is inserted into the lacrimal canaliculus of the patient an exposed surface of the drug core is in direct contact with tear fluid to permit diffusion of the therapeutic agent into the tear fluid of the eye of the patient.
16. The method of claim 15 , wherein the prostaglandin analogue is selected from the group consisting of latanoprost, bimatoprost, and travoprost.
17. The method of claim 15 , wherein the therapeutic agent is dexamethasone, diclofenac, or a peptide.
18. The method of claim 15 , wherein the matrix comprises a non-biodegradable polymer selected from the group consisting of silicone, an acrylate, a polyethylene, polyurethane, and polyester.
19. The method of claim 15 , wherein the therapeutic agent treats glaucoma, post-surgical inflammation, dry eye, post-surgical pain, infection, or allergies.
20. The method of claim 15 , wherein the drug insert is further configured to release the therapeutic agent for at least 21 days.